Clinical trial
A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients
NCT00006208 is registered in ClinicalTrials.gov with Triangle Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients
- Lead sponsor
- Triangle Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- August 31, 2000
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.